FL33-03 CAR-T therapy
Phase 1Cell therapy
FL33-03 CAR-T therapy is one of 6 small molecule programs targeting Acute Myeloid Leukaemia. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Acute Myeloid Leukaemia
#DrugCompanyPhaseTrials
1Cytosar
TevaPhase 3
Fludara
SanofiPhase 3
Mylotarg
WWyeth-Lederle Vaccines
Phase 3
Busulfex
Akero TherapeuticsPhase 3
Liposomal Daunorubicin
SanofiPhase 3
FL33-03 CAR-T therapy
BBeijing GoBroad Hospital
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Myeloid Leukaemia1 trial
Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia
Recruiting·—·Phase 1·NCT06326021·27 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FL33-03 CAR-T therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- BBeijing GoBroad Hospital